Navigation Links
ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
Date:3/29/2008

Will direct thrombin inhibitor excel with high-dose clopidogrel on board?

CHICAGO, March 29 /PRNewswire/ -- A large randomized trial will shed light on the ideal combination of medications for preventing unwanted blood clotting during and shortly after percutaneous coronary intervention (PCI). Specifically, study investigators expect to determine whether bivalirudin, a direct inhibitor of the clotting protein thrombin, is better than unfractionated heparin, an indirect thrombin inhibitor, in patients who have also been treated with high-dose clopidogrel.

The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 3 (ISAR-REACT 3) study is being presented today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Bivalirudin has outperformed unfractionated heparin in some previous studies of PCI, but it's not clear how the two anti-clotting medications measure up when used in combination with what has become standard protocol in the cardiac catheterization laboratory: preloading with a 600-mg dose of clopidogrel, a medication that prevents clotting by inhibiting platelets.

"The distinguishing feature of our study is that a double-blind comparison of the two different anti-thrombotic regimens was performed against a backdrop of optimal oral anti-platelet loading therapy," said Adnan Kastrati, MD, a professor of cardiology and head of the catheterization laboratory at Deutsches Herzzentrum and Technical University, Munich, Germany. "We hypothesized that in patients who were optimally pre-treated with clopidogrel, bivalirudin would continue to prove superior to unfractionated heparin, at least in terms of safety -- by reducing bleeding side effects."

Bivalirudin has several potential advantages over unfractionated heparin: It does not rely on antithrombin to achieve its effects, it has a more predictable dose-response pattern (and, therefore, does not require routine blood test monitoring) and it has a short plasma half-life, which is important if a patient develops a bleeding problem.

For the study, Dr. Kastrati and his fellow ISAR-REACT 3 investigators recruited 4,570 low-to-intermediate-risk patients who were undergoing PCI for reasons other than heart attack, randomly assigning them to receive either unfractionated heparin or bivalirudin during the procedure. All patients received 600 mg of clopidogrel at least two hours before PCI, and all patients continued to take 75 mg of clopidogrel for at least one month after balloon angioplasty or implantation of bare-metal stents, and for at least six months after implantation of drug-eluting stents. Patients continued to take aspirin indefinitely.

The study will determine whether use of bivalirudin influences rates of bleeding during the initial hospitalization or the 30-day combined rates of death, heart attack or urgent procedure to reopen the treated artery.

"This population under study is important, as it reflects the predominant group undergoing PCI, perhaps up to 70 percent," said Dr. Kastrati. "Our results may clarify the paradigm for peri-procedural adjunctive therapy in this important group."

Dr. Kastrati will present the results of the "Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 3" (ISAR-REACT 3) study on Saturday, March 29 at 8:00 a.m. CDT in the Grand Ballroom, S100.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.

About ACC

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.


'/>"/>
SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):